DBV Technologies Shares Surge by 33.51% Over the Week
DBV Technologies closed the week at €2.59, marking a significant increase of 33.51% over five sessions, contrasting with declines in the CAC 40 and SBF 120 of 1.72% and 1.75% respectively. This performance is part of an upward trend that has been developing for several weeks, with the stock showing an increase of 35.89% over three months and a spectacular gain of 272.7% over one year. Trading volumes peaked mid-week, indicating a marked resurgence of investor interest.
DBV Technologies concluded the week at €2.59, up by 33.51% over five sessions, while the CAC 40 and SBF 120 each fell by 1.72% and 1.75% respectively during the same period. This performance follows a bullish trend that started several weeks ago, with the stock up 35.89% over three months and an impressive 272.7% over the past year. Trading volumes intensified mid-week, reaching over four million shares on Wednesday, October 9th, reflecting a significant rebound in investor interest. However, Friday's session saw a slight decline to €2.59, after reaching €2.82 the previous day, in more subdued trading volumes.
Reasons Behind the Weekly Surge
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The significant weekly surge can be primarily attributed to the announcement on October 6th of a fundraising of approximately $30 million through an 'At-The-Market' program on the Nasdaq. The biopharmaceutical company issued 11,538,460 new ordinary shares in the form of 2,307,692 ADS (American Depositary Shares), priced at $13 per ADS, equivalent to €2.2264 per ordinary share. The operation, conducted with investor Invus through Citizens Capital Markets, was carried out at a price reflecting a discount of 3.41% from the last closing price on Euronext Paris before the price was set. The new shares, delivered on October 8th, represent a dilution of about 7.77% for existing shareholders. Following the announcement, the stock rose by 11.71%, recording the highest increase in the Deferred Settlement Service (SRD) at the close of Tuesday, October 7th, continuing a rally that began in late September.
Perte nette trimestrielle de (33,2) millions de dollars ; trésorerie de 69,8 millions de dollars au 30/09/2025 suite à un financement partiel (125,5 M$ reçu) et un programme ATM ; dépenses opérationnelles élevées principalement en R&D (83,8 M$ sur 9 mois). Trésorerie estimée suffisante jusqu'au T3 2026 mais incertitude significative persiste.
Risks mentioned
Incertitude significative sur la continuité d'exploitation (trésorerie insuffisante pour couvrir 12 prochains mois)
Dépendance aux financements externes (PIPE, ATM et autres levées de fonds)
Accès futur aux capitaux soumis aux conditions du marché et à l'intérêt des investisseurs
Dépendance aux résultats de l'étude de phase 3 VITESSE pour accélération d'exercices de BSA et financements supplémentaires
Opportunities identified
Financement pouvant atteindre 306,9 millions de dollars via PIPE
Programme ATM pouvant générer jusqu'à 150,0 millions de dollars
Potentiel réglementaire et commercial du patch Viaskin® Peanut (BLA et lancement aux États-Unis si approuvé)
Possibilité d'exercices supplémentaires de bons de souscription si certains critères sont atteints
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
